Evidence map›Paper›PMID 26508288›Full record

ArticleNeurochemical research2015

Competition, Selectivity and Efficacy of Analogs of A-84543 for Nicotinic Acetylcholine Receptors with Repositioning of Pyridine Nitrogen.

Adebowale E Ogunjirin, Joseph M Fortunak, LaVerne L Brown, Yingxian Xiao, Martha I Dávila-García

Abstract read
In one paragraph

Article in Neurochemical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Site-Selective Switching Strategies to Functionalize Polyazines.Journal of the American Chemical Society · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Adebowale E OgunjirinDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, 20059, USA.
Joseph M FortunakDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, 20059, USA.
LaVerne L BrownDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, 20059, USA.
Yingxian XiaoDepartment of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC, 20057, USA.
Martha I Dávila-GarcíaDepartment of Pharmacology, Howard University College of Medicine, Washington, DC, 20059, USA. mdavila-garcia@howard.edu.
Howard University · USGeorgetown University · US

Funding

The Howard University SCORE Program Supplemental GrantS06GM008016 · NIGMS · HOWARD UNIVERSITY · PI LITTLETON, GEORGE K · 1989 to 2009
$16.1M
MONOAMINERGIC NEURONS AND LIMBIC CIRCUITSR24MH067627 · NIMH · HOWARD UNIVERSITY · PI MANAYE, KEBRETEN F · 2004 to 2006
$1.4M
NIGMS NIH HHS S06 GM008016NIGMS NIH HHS S06 GM08016-34NIMH NIH HHS 5R24MH067627NIMH NIH HHS R24 MH067627
6 · The paper itself

Abstract

Nicotinic acetylcholine receptors (nAChRs) play a crucial role in a number of clinically relevant mental and neurological pathways, as well as autonomic and immune functions. The development of subtype-selective ligands for nAChRs therefore is potentially useful for targeted therapeutic management of conditions where nAChRs are involved. We tested if selectivity for a particular nAChR subtype can be achieved through small structural modifications of a lead compound containing the nicotinic pharmacophore by changing the distance between the electronegative elements. For this purpose, analogs of A-84543 were designed, synthesized and characterized as potentially new nAChR subtype-selective ligands. Compounds were tested for their binding properties in rat cerebral cortical tissue homogenates, and subtype-selectivity was determined using stably transfected HEK cells expressing different nAChR subtypes. All compounds synthesized were found to competitively displace [(3)H]-epibatidine ([(3)H]EB) from the nAChR binding site. Of all the analogues, H-11MNH showed highest affinity for nAChRs compared to a ~ fivefold to tenfold lower affinity of A-84543. All other compounds had affinities >10,000 nM. Both A-84543 and H-11MNH have highest affinity for α2β2 and α4β2 nAChRs and show moderate affinity for β4- and α7-containing receptors. H-11MNH was found to be a full agonist with high potency at α3β4, while A-84543 is a partial agonist with low potency. Based on their unique pharmacological binding properties we suggest that A-84543 and its desmethylpyrrolidine analog can be useful as pharmacological ligands for studying nAChRs if selective pharmacological and/or genetic tools are used to mask the function of other receptors subtypes.

Indexed as

AnimalsBridged Bicyclo Compounds, HeterocyclicHumansNeuronsNicotineNitrogenPyridinesPyrrolidinesRatsReceptors, NicotinicStructure-Activity Relationship3-(2-(pyrrolidinyl)methoxy)pyridineBridged Bicyclo Compounds, HeterocyclicepibatidineNicotineNitrogenpyridinePyridinesPyrrolidinesReceptors, NicotinicA-85380Cerebral cortexEpibatidineH-11MNHNicotineSaturation

Identifiers

PMID26508288
PMCPMC4741274
OpenAlexW1871902501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.